GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Huluwa Pharmaceutical Group Co Ltd (SHSE:605199) » Definitions » EV-to-EBITDA

Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) EV-to-EBITDA : 41.50 (As of May. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Hainan Huluwa Pharmaceutical Group Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hainan Huluwa Pharmaceutical Group Co's enterprise value is ¥5,557 Mil. Hainan Huluwa Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ¥134 Mil. Therefore, Hainan Huluwa Pharmaceutical Group Co's EV-to-EBITDA for today is 41.50.

The historical rank and industry rank for Hainan Huluwa Pharmaceutical Group Co's EV-to-EBITDA or its related term are showing as below:

SHSE:605199' s EV-to-EBITDA Range Over the Past 10 Years
Min: 18.35   Med: 61.9   Max: 113.47
Current: 41.53

During the past 8 years, the highest EV-to-EBITDA of Hainan Huluwa Pharmaceutical Group Co was 113.47. The lowest was 18.35. And the median was 61.90.

SHSE:605199's EV-to-EBITDA is ranked worse than
87.38% of 713 companies
in the Drug Manufacturers industry
Industry Median: 14.45 vs SHSE:605199: 41.53

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), Hainan Huluwa Pharmaceutical Group Co's stock price is ¥11.31. Hainan Huluwa Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.240. Therefore, Hainan Huluwa Pharmaceutical Group Co's PE Ratio for today is 47.13.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Hainan Huluwa Pharmaceutical Group Co EV-to-EBITDA Historical Data

The historical data trend for Hainan Huluwa Pharmaceutical Group Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hainan Huluwa Pharmaceutical Group Co EV-to-EBITDA Chart

Hainan Huluwa Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - 51.28 69.48 39.79 32.28

Hainan Huluwa Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.34 50.97 49.27 32.28 44.78

Competitive Comparison of Hainan Huluwa Pharmaceutical Group Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Huluwa Pharmaceutical Group Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hainan Huluwa Pharmaceutical Group Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hainan Huluwa Pharmaceutical Group Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hainan Huluwa Pharmaceutical Group Co's EV-to-EBITDA falls into.



Hainan Huluwa Pharmaceutical Group Co EV-to-EBITDA Calculation

Hainan Huluwa Pharmaceutical Group Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=5557.251/133.923
=41.50

Hainan Huluwa Pharmaceutical Group Co's current Enterprise Value is ¥5,557 Mil.
Hainan Huluwa Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥134 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hainan Huluwa Pharmaceutical Group Co  (SHSE:605199) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Hainan Huluwa Pharmaceutical Group Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=11.31/0.240
=47.13

Hainan Huluwa Pharmaceutical Group Co's share price for today is ¥11.31.
Hainan Huluwa Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Hainan Huluwa Pharmaceutical Group Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Hainan Huluwa Pharmaceutical Group Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Business Description

Traded in Other Exchanges
N/A
Address
No. 8, Yaogu 4th Road, Phase II, Yaogu Industrial Park, Haikou National High-tech Zone, Hainan Province, Haikou, CHN, 570300
Hainan Huluwa Pharmaceutical Group Co Ltd is engaged in production and sales of Chinese patent medicines and chemical drugs. The company produces medicines for children's respiratory and digestive systems. Its products include star products, calabash, gourd dad, and gourd mom.

Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Headlines

No Headlines